atorvastatin + placebo

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerotic Vascular Disease

Conditions

Atherosclerotic Vascular Disease

Trial Timeline

Aug 1, 2008 → Dec 1, 2009

About atorvastatin + placebo

atorvastatin + placebo is a phase 1 stage product being developed by Merck for Atherosclerotic Vascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00703261. Target conditions include Atherosclerotic Vascular Disease.

What happened to similar drugs?

8 of 20 similar drugs in Atherosclerotic Vascular Disease were approved

Approved (8) Terminated (0) Active (12)
Rosuvamibe + MonorovaYuhanApproved
Rosuvamibe + MonorovaYuhanApproved
Clopidogrel + TicagrelorAstraZenecaApproved
atorvastatin + inclisiranNovartisApproved
InclisiranNovartisApproved
EvolocumabAmgenApproved
Placebo + EvolocumabAmgenApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00703261Phase 1Completed

Competing Products

20 competing products in Atherosclerotic Vascular Disease

See all competitors